荷兰全科实践中老年患者降脂药处方模式:基于全国数据库的分析
基于荷兰415家全科诊所2011-15年电子健康记录中244,328名≥70岁成人,分析降脂药处方与年龄、衰弱及共病的关系。有心血管疾病者约69%被处方降脂药,无心血管疾病者约36%;处方率随年龄增长而下降,但在相同年龄段内衰弱者处方率反而更高。
要点
- ≥70岁有心血管疾病者约69%、无心血管疾病者约36%被处方降脂药。
- 降脂药处方率随年龄增长而下降,有心血管疾病者70-74岁为78%、≥90岁为29%。
- 相同年龄段内,衰弱者降脂药处方率高于非衰弱者,有心血管疾病者高20个百分点。
核心结论
- 在老年人群中,降脂药处方率随年龄增长而下降,但与预期相反,降脂药处方率随衰弱程度升高而增加。
研究设计与样本
- 基于荷兰415家全科诊所2011-15年电子健康记录,纳入244,328名≥70岁成人,其中55,309名有心血管疾病、189,019名无心血管疾病。
主要发现
- 有心血管疾病者约69%被处方降脂药,无心血管疾病者约36%。
- 有心血管疾病者中,70-74岁78%被处方降脂药,≥90岁29%;无心血管疾病者中,70-74岁37%,≥90岁12%。
- 有心血管疾病且在同一年龄段内,衰弱者降脂药处方率比非衰弱者高20个百分点。
- 无心血管疾病者中,衰弱者降脂药处方率在70-74岁比非衰弱者高11个百分点,在≥90岁高40个百分点。
- 按共病数量分析也观察到类似趋势。
临床怎么用
- 老年医学科医生应认识到降脂药处方决策需综合年龄、衰弱和共病,而非仅依据心血管疾病指南的广泛适用性。
- 对高龄衰弱患者处方降脂药时,应评估预期寿命与获益风险,避免仅因衰弱而增加处方。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dutch cardiovascular risk management guidelines state almost every older adult (≥70 years) is eligible for a lipid lowering drug (LLD). However, life expectancy, frailty or comorbidities may influence this treatment decision. OBJECTIVE: investigate how many older adults, according to age, frailty (Drubbel-frailty index) and comorbidities were prescribed LLDs. METHODS: data of 244,328 adults ≥70 years from electronic health records of 415 Dutch general practices from 2011-15 were used. Number of LLD prescriptions in patients with (n = 55,309) and without (n = 189,019) cardiovascular disease (CVD) was evaluated according to age, frailty and comorbidities. RESULTS: about 69% of adults ≥70 years with CVD and 36% without CVD were prescribed a LLD. LLD prescriptions decreased with age; with CVD: 78% aged 70-74 years and 29% aged ≥90 years were prescribed a LLD, without CVD: 37% aged 70-74 years and 12% aged ≥90 years. In patients with CVD and within each age group, percentage of LLD prescriptions was 20% point(pp) higher in frail compared with non-frail. In patients without CVD, percentage of LLD prescriptions in frail patients was 11pp higher in adults aged 70-74 years and 40pp higher in adults aged ≥90 years compared to non-frail. Similar trends were seen in the analyses with number of comorbidities. CONCLUSION: in an older population, LLD prescriptions decreased with age but-contrary to our expectations-LLD prescriptions increased with higher frailty levels.
引用
- Kleipool EEF, Nielen MMJ, Korevaar JC, et al. Prescription patterns of lipid lowering agents among older patients in general practice: an analysis from a national database in the Netherlands. Age Ageing. 2019. PMID: 31074492. doi:10.1093/ageing/afz034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。